LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

ABSTRACT:

Background

No blood test has been shown to be effective in the prediction of primary liver cancer in patients without cirrhosis.

Aim

To construct and internally validate two sequential tests for early prediction of liver cancer. These tests enable an algorithm which could improve the performance of the standard surveillance protocol recommended (imaging with or without AFP), limited to patients with cirrhosis.

Methods

We performed a retrospective analysis in prospectively collected specimens from an ongoing cohort. We designed an early sensitive high-risk test (LCR1) that combined (using Cox model) hepatoprotective proteins (apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a marker of fibrosis (alpha2-macroglobulin

SUBMITTER: Poynard T 

PROVIDER: S-EPMC6590635 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature